bioMérieux – Third-Quarter 2021 Business Review

Marcy l’Étoile, October 21, 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

• Organic growth of 12.1% at constant exchange rates and scope of consolidation over the first nine months of the year:
  • €2,452 million in sales
  • Up 8.2% as reported

• Q3 sales organic growth at 11.6%, significantly...

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

Marcy l’Étoile, France and London, UK – September 13th, 2021 –  On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths from sepsis and improve outcome for its survivors, reveal the results of a survey conducted in Europe* regarding knowledge and attitudes towards sepsis. The findings demonstrate the need to accelerate awareness and education of the general population about this life-threatening condition.

Sepsis is a life-threatening organ dysfunction caused by an excessive immune response to a serious infection. Every year worldwide 49 million people develop  sepsis, of whom 11 million do not survive.

bioMérieux has long been committed to the fight against sepsis and is working...

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL^® Rapid AST system in Europe

Marcy l’Étoile, France and Mountain View, California – bioMérieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems to clinical microbiology, announce that bioMérieux will distribute Specific Diagnostics’ newly introduced REVEAL Rapid AST system in Europe.

In the context of the global threat from Antimicrobial Resistance (AMR), clinicians need to receive faster antibiotic susceptibility test (AST) results and accurate interpretation, to enable timely and optimized patient intervention. In bloodstream infections, an urgent and often life-...

bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS^® SARS-COV-2 IgG II serology test.  

bioMérieux, a world leader in the field of in vitro diagnostics, today announces CE marking of the new generation of IgG serology test with VIDAS^® SARS-COV-2 IgG II to semi-quantitatively detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.

In 2021, on top of the importance of detecting COVID-19 virus, the emergence of variant strains and expansion of vaccination have generated new public health challenges. In particular, obtaining quantitative serological information by measuring antibody levels might provide important insights to...